Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice
Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice
复制标题
DOI：
10.1016/j.ejphar.2006.09.011
复制
发表时间：
2006-12-15
影响因子：
5
通讯作者：
Ko, Kam-Ming
中科院分区：
文献类型：
--
作者：
Pan, Si-Yuan;Yang, Rong;Ko, Kam-Ming
本文研究了五味子乙素的合成中间体联苯双酯对实验性高胆固醇血症小鼠肝脏脂质含量的影响。通过长期给予胆固醇/胆盐或喂食含有胆固醇和/或胆盐的高脂肪饮食诱导高胆固醇血症。与接受溶媒或正常饲料的对照动物相比，胆固醇或高脂肪饲料给药小鼠的肝脏和血清总胆固醇水平显著升高（分别为42-268%和23- 124%）。在高胆固醇血症小鼠中，肝脏甘油三酯水平升高（高达108%），但血清甘油三酯水平显著降低23-63%。联苯双酯（0.03- 1.0g/kg，i.g.）持续4天降低了高胆固醇血症小鼠的总胆固醇（9-37%）和甘油三酯（10-37%）的肝脏水平。与喂食未补充联苯双酯的高脂肪饲料的动物相比，在实验7或14天后，分别用联苯双酯（0.25%，w/w）补充高脂肪饲料导致肝脏总胆固醇（25-56%）和甘油三酯（22-44%）水平降低。虽然非诺贝特治疗降低了高胆固醇血症小鼠的肝脏和血清脂质水平，联苯双酯治疗没有降低血清脂质水平。联苯双酯和非诺贝特引起高胆固醇血症小鼠的肝指数增加（分别为10-41%和59- 98%）。结果表明，联苯双酯治疗可以总是降低肝脏（但不是血清）的脂质水平在各种小鼠模型的高胆固醇血症。(c)2006 Elsevier B. V.保留所有权利。
Effects of bifendate, a synthetic intermediate of schisandrin C (a dibenzocyclooctadiene derivative), on liver lipid contents were investigated in experimentally-induced hypercholesterolemia in mice. Hypercholesterolemia was induced by either chronic administration of cholesterol/bile salt or feeding a high-fat diet containing cholesterol and/or bile salt. Hepatic and serum total cholesterol levels were significantly increased (42-268% and 23-124%, respectively) in cholesterol or high-fat diet-treated mice, when compared with control animals receiving vehicle or normal diet. Hepatic triglyceride level was increased (up to 108%), but serum triglyceride level was significantly reduced by 23-63% in hypercholesterolemic mice. Daily administration of bifendate (0.03-1.0 g/kg, i.g.) for 4 days decreased hepatic levels of total cholesterol (9-37%) and triglyceride (10-37%) in hypercholesterolemic mice. Supplementing the high-fat diet with bifendate (0.25%, w/w) caused decreases in hepatic total cholesterol (25-56%) and triglyceride (22-44%) levels following 7 or 14 days of experiment, respectively, when compared with animals fed with high-fat diet not supplemented with bifendate. While fenofibrate treatment decreased both hepatic and serum lipid levels in hypercholesterolemic mice, bifendate treatment did not reduce serum lipid levels. Bifendate and fenofibrate caused an increase (10-41% and 59-98%, respectively) in hepatic index of hypercholesterolemic mice. The results indicate that bifendate treatment can invariably decrease hepatic (but not serum) lipid levels in various mouse models of hypercholesterolemia. (c) 2006 Elsevier B.V. All rights reserved.